Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?

Akhil Rajendra, Elliot Smith, Eshetu Atenafu, Aniket Bankar, Steven M. Chan, Marta Beata Davidson, Vikas Gupta, Mark D. Minden, Maria Agustina Perusini, Guillaume Richard-Carpentier, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn C. Maze

Blood (2024) 144 (Supplement 1): 5193.

https://doi.org/10.1182/blood-2024-208884

Published: 2024

Journal Articles

Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations

Elliot Smith, Akhil Rajendra Kurup, Eshetu Atenafu, Aniket Bankar, Steven M. Chan, Marta Beata Davidson, Vikas Gupta, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn C. Maze

Blood (2024) 144 (Supplement 1): 1483.

https://doi.org/10.1182/blood-2024-202069

Published: 2024

Journal Articles

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Jorge E. Cortes, Gail J. Roboz, Justin M. Watts, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, Brent Ferrell, Jay Yang, Eunice S. Wang, William Blum, Alice Mims

Blood (2024) 144 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2024-201710

Published: 2024

Journal Articles

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Blood (2024) 144 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2024-204004

Published: 2024

Journal Articles

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Blood (2024) 144 (Supplement 1): 4583.

https://doi.org/10.1182/blood-2024-194441

Published: 2024

Journal Articles

FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience

Eshrak Al-Shaibani, Marta Beata Davidson, Aniket Bankar, Steven M. Chan, Hassan Sibai, Dawn C. Maze, Aaron D Schimmer, Mark D. Minden, Karen Yee, Vikas Gupta, Andre C. Schuh, Guillaume Richard-Carpentier

Blood (2024) 144 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2024-209476

Published: 2024

Journal Articles

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Eunice S. Wang, Jorge E. Cortes, Justin M. Watts, Brian A. Jonas, Andrew H Wei, Jay Yang, Joseph G Jurcic, Gail J. Roboz, Karen Seiter, Alice Mims, Karen Yee, Brent Ferrell, Shira N. Dinner, William B. Donnellan, William Blum, Francois Di Trapani, Hua Tian, Stephane De Botton

Blood (2024) 144 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2024-198504

Published: 2024

Journal Articles

Clinical Relevance of NPM1 Quantitative PCR As Standard of Care with Different Cut-Off Values on Treatment Outcomes in NPM1-Mutated Acute Myeloid Leukemia Patients

Donna Zhe Sian Eng, Andre C. Schuh, Aniket Bankar, Marta Beata Davidson, Guillaume Richard-Carpentier, Hassan Sibai, Dawn C. Maze, Karen Yee, Aaron D Schimmer, Vikas Gupta, Tracy Stockley, Jose-Mario Capo-Chichi, Chen Steven, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 6172.

https://doi.org/10.1182/blood-2024-211783

Published: 2024

Journal Articles

Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia

Swe Mar Linn, Nihar Desai, Steven M. Chan, Andre C. Schuh, Aniket Banker, Marta Beata Davidson, Guillaume Richard-Carpentier, Aron Shimmer, Dawn C. Maze, Karen Yee, Mark D. Minden, Vikas Gupta, Tracy Stockley, Hassan Sibai, Jose-Mario Capo-Chichi, Anne Maria Tierens, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 1570.

https://doi.org/10.1182/blood-2024-211434

Published: 2024

Journal Articles

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Blood (2024) 144 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2024-211183

Published: 2024

Journal Articles

Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials

Samuel Urrutia, Koji Sasaki, Alex Bataller, Hagop M. Kantarjian, Guillermo Montalban-Bravo, James McCloskey, Elizabeth A. Griffiths, Karen Yee, Amer M. Zeidan, Michael R. Savona, Aram Oganesian, Yuri Sano, Harold N. Keer, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 661.

https://doi.org/10.1182/blood-2024-193274

Published: 2024

Journal Articles

Preliminary Results from a Phase 1b/2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine in Patients (Pts) with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)

Brian A. Jonas, Karen Yee, Alice Mims, Paul B. Koller, Joseph Brandwein, Gail J. Roboz, Glenn Michelson, Linh Nguyen, Mark R Bray, Emily Roberts-Thomson, Roger Sidhu, Gautam Borthakur

Blood (2023) 142 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2023-182027

Published: 2023

Journal Articles

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2023-173302

Published: 2023

Journal Articles

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

Naval Daver, Anthony Selwyn Stein, Dale Bixby, Wanxing Chai-Ho, Joshua F. Zeidner, Keri Maher, Don A. Stevens, Maximilian Stahl, Karen Yee, Emily K Curran, Sawa Ito, Andrew Sochacki, David A Sallman, Robert Hernandez, Simon Metenou, Bo Ma, Kazunobu Kato, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4278.

https://doi.org/10.1182/blood-2023-173991

Published: 2023

Journal Articles

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Josephine Anne Lucero, Aniket Bankar, Marta Beata Davidson, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Dawn C. Maze, Karen Yee, Mark D. Minden, Steven M. Chan, Jonas Mattsson, Rajat Kumar, Vikas Gupta, Jose-Mario Capo-Chichi, Tracy Stockley, Hassan Sibai, Anne Maria Tierens, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2023-190694

Published: 2023

Journal Articles

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Guillaume Richard-Carpentier, Gopila Gupta, Charina Cameron, Severine Cathelin, Aniket Bankar, Marta Beata Davidson, Vikas Gupta, Dawn C. Maze, Mark D. Minden, Tracy Murphy, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Joseph Brandwein, Caroline Jane McNamara, Steven M. Chan

Blood (2023) 142 (Supplement 1): 159.

https://doi.org/10.1182/blood-2023-188341

Published: 2023

Journal Articles

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Maria Agustina Perusini, Jad Sibai, Eshetu G. Atenafu, Aniket Bankar, Mark D. Minden, Vikas Gupta, Dawn Maze, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Guillaume Richard-Carpentier, Josephine Anne Lucero, Claire Andrews, Dennis Dong Hwan Kim, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 6039–6041.

https://doi.org/10.1182/blood-2022-169406

Published: 2022

Journal Articles

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Maria Agustina Perusini, Eshetu G. Atenafu, Aniket Bankar, Vikas Gupta, Mark D. Minden, Jad Sibai, Dawn Maze, Marta B. Davidson, Steven M. Chan, Fernando Binder, Guillaume Richard-Carpentier, Salman Alharbi, Claire Andrews, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3176–3177.

https://doi.org/10.1182/blood-2022-170121

Published: 2022

Journal Articles

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Fatima M Khadadah, Claire Andrews, Eshetu G. Atenafu, Andre C. Schuh, Dawn Maze, Karen Yee, Osamah Jamal S. Jarallah, Mark D. Minden, Aaron D. Schimmer, Steven M. Chan, Vikas Gupta, Dennis Dong Hwan Kim, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3169–3171.

https://doi.org/10.1182/blood-2022-169342

Published: 2022

Journal Articles

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Blood (2022) 140 (Supplement 1): 2066–2069.

https://doi.org/10.1182/blood-2022-163841

Published: 2022

NARROW

What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?

Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Clinical Relevance of NPM1 Quantitative PCR As Standard of Care with Different Cut-Off Values on Treatment Outcomes in NPM1-Mutated Acute Myeloid Leukemia Patients

Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only